ATHX
Price:
$0.1018
Market Cap:
$6.28M
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy ...[Read more]
Industry
Biotechnology
IPO Date
2007-06-12
Stock Exchange
NASDAQ
Ticker
ATHX
According to Athersys, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 23.84M. This represents a change of -13.14% compared to the average of 27.44M of the last 4 quarters.
The mean historical Enterprise Value of Athersys, Inc. over the last ten years is 131.83M. The current 23.84M Enterprise Value has changed 1.71% with respect to the historical average. Over the past ten years (40 quarters), ATHX's Enterprise Value was at its highest in in the March 2020 quarter at 455.45M. The Enterprise Value was at its lowest in in the December 2022 quarter at 13.59M.
Average
131.83M
Median
130.78M
Minimum
10.43M
Maximum
277.21M
Discovering the peaks and valleys of Athersys, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.13%
Maximum Annual Enterprise Value = 277.21M
Minimum Annual Increase = -94.01%
Minimum Annual Enterprise Value = 10.43M
Year | Enterprise Value | Change |
---|---|---|
2022 | 10.43M | -94.01% |
2021 | 174.21M | -37.16% |
2020 | 277.21M | 82.92% |
2019 | 151.55M | 4.01% |
2018 | 145.70M | -16.02% |
2017 | 173.50M | 49.74% |
2016 | 115.86M | 87.57% |
2015 | 61.77M | -35.42% |
2014 | 95.64M | -14.92% |
2013 | 112.42M | 1.13% |
The current Enterprise Value of Athersys, Inc. (ATHX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
153.95M
5-year avg
151.82M
10-year avg
131.83M
Athersys, Inc.’s Enterprise Value is greater than LianBio (-66141903.00), less than Eton Pharmaceuticals, Inc. (105.77M), greater than Galera Therapeutics, Inc. (-5475585.00), less than Checkpoint Therapeutics, Inc. (88.12M), less than YS Biopharma Co., Ltd. (1.69B), greater than Sonnet BioTherapeutics Holdings, Inc. (1.13M), greater than ZyVersa Therapeutics, Inc. (2.58M), greater than Allarity Therapeutics, Inc. (-10898430.00), greater than Kiromic BioPharma, Inc. (12.33M), greater than Avenue Therapeutics, Inc. (-868251.00), greater than Hoth Therapeutics, Inc. (-2295705.00), greater than Revelation Biosciences, Inc. (-10643144.00), greater than NeuroBo Pharmaceuticals, Inc. (1.94M), greater than Virax Biolabs Group Limited (11.88M), greater than TransCode Therapeutics, Inc. (1.43M), less than Fortress Biotech, Inc. (52.60M), less than Akebia Therapeutics, Inc. (349.01M), greater than Trevena, Inc. (23.51M), less than Reviva Pharmaceuticals Holdings, Inc. (39.93M), less than Pyxis Oncology, Inc. (200.62M), less than Zura Bio Limited (42.42M), greater than eFFECTOR Therapeutics, Inc. (3.83M), greater than Altamira Therapeutics Ltd. (1.20M), greater than Elevation Oncology, Inc. (8.41M),
Company | Enterprise Value | Market cap |
---|---|---|
-66141903.00 | $34.47M | |
105.77M | $118.59M | |
-5475585.00 | $4.08M | |
88.12M | $93.07M | |
1.69B | $192.09M | |
1.13M | $4.53M | |
2.58M | $2.70M | |
-10898430.00 | $7.01M | |
12.33M | $3.14M | |
-868251.00 | $4.05M | |
-2295705.00 | $7.32M | |
-10643144.00 | $1.43M | |
1.94M | $29.70M | |
11.88M | $15.24M | |
1.43M | $4.56M | |
52.60M | $40.38M | |
349.01M | $283.89M | |
23.51M | $3.40M | |
39.93M | $44.68M | |
200.62M | $206.30M | |
42.42M | $230.86M | |
3.83M | $188.18K | |
1.20M | $2.04M | |
8.41M | $36.94M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Athersys, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Athersys, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Athersys, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Athersys, Inc. (ATHX)?
What is the 3-year average Enterprise Value for Athersys, Inc. (ATHX)?
What is the 5-year average Enterprise Value for Athersys, Inc. (ATHX)?
How does the current Enterprise Value for Athersys, Inc. (ATHX) compare to its historical average?